Upcoming Endocrine Therapy Developments Excite in Breast Cancer
Erika Hamilton, MD, discusses how novel endocrine therapies improve treatment for metastatic breast cancer.
Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses how novel endocrine therapies improve treatment for metastatic breast cancer.
She also discusses what upcoming developments in the breast cancer space she is most excited about.
Transcription:
0:09 | What we are seeing is that CDK4/6’s are really the mainstay of our treatment. In the first-line, they extended progression-free survival by almost a year, improving overall survival in many cases. However, post-CDK4/6, drugs we used to [rely on], like fulvestrant, are not performing as well as they used to. Now, we have 2 randomized trials in that second-line, post-CDK4/6 setting, where fulvestrant gives us a progression-free survival of less than 2 months, which is certainly not good enough for our patients.
0:45 | I think the unmet clinical needs are for these patients whose tumors remain endocrine-sensitive. We need better endocrine therapy so they can remain on endocrine therapies or endocrine combinations and delay having to move to other treatments with more toxicities, such as chemotherapy.
1:03 | There are a lot of trials ongoing. First, there are multiple companies developing novel endocrine agents, and they are diversifying their approaches. The area that will likely be actionable first is the second-line, post-CDK space. However, there are also ongoing trials in the first-line setting, in combination with CDK4/6 inhibitors, as a switch strategy for positive [circulating tumor] DNA, with results expected to read-out relatively soon.
1:30 | And then also, there are adjuvant trials for curative breast cancer that may replace our traditional endocrine backbones. These trials come in 2 varieties: one comparing the new agents up front with aromatase inhibitors, and another using a switch strategy after 2 to 5 years on an aromatase inhibitor. With all these trials ongoing, we will certainly have a rich data set to improve our endocrine therapies.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
